Loading...
Please wait, while we are loading the content...
Similar Documents
How to judge animal models of Parkinson's disease in terms of neuroprotection.
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2006 |
| Abstract | Ideally, animal models of Parkinson's should reproduce the clinical manifestation of the disease, a loss of some but not all dopaminergic neurons, a loss of some non dopaminergic neurons and alpha-synuclein positive inclusions resembling Lewy bodies. There are at least three ways to develop animal models of PD. The first two are based on the etiology of the disease and consist in 1) reproducing in animals the mutations seen in inherited forms of PD; 2) intoxicating animals with putative environmental toxins causing PD. The last method currently used, which is not exclusive of the first two, is to try to reproduce the molecular or biochemical changes seen post-mortem in the brain of patients with PD. In this review we discuss the advantages and the drawbacks in term of neuroprotection of the currently used models. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://eknygos.lsmuni.lt/springer/340/5.Models/2%20Item.pdf |
| PubMed reference number | 17017538v1 |
| Volume Number | 70 |
| Journal | Journal of neural transmission. Supplementum |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Animal Model Anti-Inflammatory Agents Biologic Preservation Dopamine Hydrochloride Dopaminergic Neurons Inclusion Bodies Lewy Bodies Monoamine Oxidase Mutation Neuroprotection PPAR gamma Parasitic Diseases, Animal Parkinson Disease Parkinsonian Disorders Patients Peroxisome Proliferators Substantia nigra structure Synucleins Toxin alpha-Synuclein pioglitazone |
| Content Type | Text |
| Resource Type | Article |